论文部分内容阅读
目的:观察比较三拗片联合抗生素与盐酸氨溴索片联合抗生素治疗急慢性支气管炎的临床疗效和安全性。方法:将185例急性支气管炎和慢性支气管炎急性发作患者随机分为两组,A组予三拗片联合抗生素治疗,B组予盐酸氨溴索片联合抗生素治疗,比较两组患者呼吸道症状评分、症状持续时间、总体疗效、使用沙丁胺醇气雾剂的比例以及不良反应。结果:治疗后两组症状评分均明显下降(均P<0.05),治疗后A组咳嗽、咳痰、气喘及肺部哮鸣音症状评分明显低于B组(均P<0.05),咳嗽、气喘和肺部哮鸣音的症状持续时间均明显短于B组(均P<0.05),咳痰症状的持续时间虽短于B组但差异无统计学意义(P>0.05);A组总体治疗有效率(93.5%)高于B组的82.8%(P=0.025);A组患者使用β2受体激动剂的比例低于B组,且未发现明显不良反应。结论:三拗片可改善急性支气管炎及慢性支气管炎急性发作患者的呼吸道症状,安全有效,值得临床推广应用。
OBJECTIVE: To observe the clinical efficacy and safety of the combination of Sanmao tablets combined with antibiotics and ambroxol hydrochloride in the treatment of acute and chronic bronchitis. Methods: A total of 185 patients with acute bronchitis and acute exacerbation of chronic bronchitis were randomly divided into two groups: group A was treated with Sanhuo tablets combined with antibiotics; group B was treated with ambroxol hydrochloride combined with antibiotics; respiratory symptom scores were compared between the two groups , Duration of symptoms, overall response, ratio of salbutamol aerosol use, and adverse reactions. Results: After treatment, the symptom scores of both groups were significantly decreased (all P <0.05). After treatment, the cough, sputum, asthma and lung wheeze symptom scores in group A were significantly lower than those in group B (all P <0.05) Asthma and lung wheeze symptoms were significantly shorter duration than in group B (all P <0.05), duration of sputum symptoms were shorter than the group B but the difference was not statistically significant (P> 0.05); group A The effective rate of treatment (93.5%) was higher than that of group B (82.8%) (P = 0.025). The ratio of β2 receptor agonist in group A was lower than that in group B, and no obvious adverse reaction was found. Conclusion: Sanwei tablet can improve respiratory symptoms of patients with acute bronchitis and acute exacerbation of chronic bronchitis, which is safe and effective and worthy of clinical application.